Long-Term Outcomes of Children With Trisomy 13 and 18 After Congenital Heart Disease Interventions Jennifer K. Peterson, MS, Lazaros K. Kochilas, MD, MSCR, Kirsti G. Catton, MSN, James H. Moller, MD, Shaun P. Setty, MD The Annals of Thoracic Surgery Volume 103, Issue 6, Pages 1941-1949 (June 2017) DOI: 10.1016/j.athoracsur.2017.02.068 Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions
Fig 1 Kaplan-Meier conditioned survival after intervention for congenital heart defect in trisomy 13 and 18 patients. (CI = confidence interval.) The Annals of Thoracic Surgery 2017 103, 1941-1949DOI: (10.1016/j.athoracsur.2017.02.068) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions
Fig 2 Kaplan-Meier conditioned survival after intervention for congenital heart defect in trisomy 13 and 18 patients by treatment pathway. (CI = confidence interval.) The Annals of Thoracic Surgery 2017 103, 1941-1949DOI: (10.1016/j.athoracsur.2017.02.068) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions
Fig 3 Kaplan-Meier conditioned survival after intervention for congenital heart disease in mosaic and not mosaic trisomy 13 and 18 patients. (CI = confidence interval.) The Annals of Thoracic Surgery 2017 103, 1941-1949DOI: (10.1016/j.athoracsur.2017.02.068) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions
Fig 4 Mean pulmonary arterial pressure (PAP) and pulmonary vascular resistance (PVR) in trisomy 13 and 18 patients with ventricular septal defect. (IQR = interquartile range.) The Annals of Thoracic Surgery 2017 103, 1941-1949DOI: (10.1016/j.athoracsur.2017.02.068) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions
Supplemental Figure 1 The Annals of Thoracic Surgery 2017 103, 1941-1949DOI: (10.1016/j.athoracsur.2017.02.068) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions